Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 86Breast Neoplasms 15Neoplasms 6Multiple Myeloma 3Lymphoma, Non-Hodgkin 3Salivary Gland Neoplasms 2Prostate Adenocarcinoma 2Myelodysplastic Syndromes 2Leukemia, Myeloid, Acute 2Leiomyoma 2Hodgkin Disease 2Uveal Melanoma 1Uterine Neoplasms 1Urogenital Neoplasms 1Skin Neoplasms 1Skin Diseases 1Salivary Gland Neoplasm Duct 1Recurrence 1Rare Diseases 1Prostatic Diseases 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycystic Ovary Syndrome 1PSA Level Greater Than Two 1Obesity, Morbid 1Newly Diagnosed Oligometastatic Prostate Cancer 1Neoplasms, Glandular and Epithelial 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Melanoma 1Lymphoma, Mantle-Cell 1

Interventions

nirogacestat 1luprolide acetate gel depot 1exemestane 1etoposide phosphate 1darolutamide 1X-Rays 1Taxes 1Specimen Handling 1Platinum 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Leuprolide 1Immunoglobulin G 1Disulfides 1Cisplatin 1Carboplatin 1Bleomycin 1Bevacizumab 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Granulosa cell tumor of the ovary × Leuprolide × Clear all
NCT06169124 2026-05-13

Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
37 enrolled

Granulosa cell tumor of the ovary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡